First-in-Human Study to Evaluate AMG 579 in Healthy Subjects and Patients With Stable Schizophrenia
NCT01568203
·
clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
50
Enrollment
INDUSTRY
Sponsor class
Stopped
Amgen decision (business)
Conditions
Schizophrenia
Interventions
DRUG:
AMG 579
DRUG:
Placebo
Sponsor
Amgen